Pure Global

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - Trial NCT06232707

Access comprehensive clinical trial information for NCT06232707 through Pure Global AI's free database. This Phase 3 trial is sponsored by Celgene and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 466 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06232707
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06232707
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM

Study Focus

Multiple Myeloma

Alnuctamab

Interventional

drug

Sponsor & Location

Celgene

Birmingham,Los Angeles,Stanford,New Haven,New Orleans,Baltimore,Hackensack,Summit,New York,Cincinnati,Cleveland,Providence,Watertown,Dallas,Seattle,Florencio Varela,La Plata,Pilar,Buenos Aires,Liverpo, Argentina,Australia,Austria,Belgium,Brazil,Canada,Chile,China,Czech,France,Germany,Greece,Hungary,In

Timeline & Enrollment

Phase 3

Mar 13, 2024

Sep 21, 2030

466 participants

Primary Outcome

Progression-free Survival (PFS)

Summary

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to
 standard of care regimens in participants with relapsed or refractory multiple myeloma
 (RRMM).

ICD-10 Classifications

Multiple myeloma
Multiple myeloma and malignant plasma cell neoplasms
Other myeloid leukaemia
Myeloid leukaemia
Other myelodysplastic syndromes

Data Source

ClinicalTrials.gov

NCT06232707

Non-Device Trial